Lipid minor constituents in wines. A biochemical approach in the French paradox

International Journal of Wine Research

Volumn 1, Issue 1, 2009, Pages 131-143

  Fragopoulou, E ^a   Demopoulos, C A ^b   Antonopoulou, S ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atherosclerosis; Bioactive compounds; Lipids; Platelet activating factor; Wine

Indexed keywords

EID: 74149089215     PISSN: None     EISSN: 11791403     Source Type: Journal    
DOI: 10.2147/IJWR.S4587     Document Type: Review

References (114)

1. Keys A. Coronary heart disease in seven countries. 1970. Nutrition. 1997;13(3):250-252.
2. Bazzano LA, He J, Ogden LG, et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr. 2002;76(1):93-99.
3. Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE. Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study. Int J Epidemiol. 2001;30(1):130-135.
4. Kok FJ, Kromhout D. Atherosclerosis - epidemiological studies on the health effects of a Mediterranean diet. Eur J Nutr. 2004;43(Suppl 1):I/2-5.
5. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty fiveyear follow-up of the seven countries study. JAMA. 1995;274(2):131-136.
6. Keys A. Seven Countries. A multivariate analysis of death and coronary heart disease. A Commonwealth Fund Book. Cambridge: Harvard University Press, 1980. p. 1-381.
7. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alphalinolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459.
8. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean diet heart study): a randomised single-blind trial. Lancet. 2002;360:1455-1461.
9. Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr. 1995;61 (6 Suppl):1360S-1367S.
10. Panagiotakos DB, Pitsavos C, Arvaniti F, et al. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev Med. 2007;44(4):335-340.
11. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339:1523-1526.
12. McMichael J. French wine and death certificates. Lancet. 1979; 1:1186-1187.
13. Law M, Wald N. Why heart disease mortality is low in France: the time lag explanation. BMJ. 1999;318(7196):1471-1476.
14. de Lorgeril M, Salen P, Paillard F, Laporte F, Boucher F, de Leiris J. Mediterranean diet and the French paradox: two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease. Cardiovasc Res. 2002;54(3):503-515.
15. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1979;1(8124):1017-1020.
16. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353:1547-1557.
17. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the MONICA Project populations. Lancet. 2000;355: 675-687.
18. Klatsky AL, Armstrong MA, Friedman GD. Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Am J Cardiol. 1997;80:416-420.
19. Rimm EB. Invited commentary - Alcohol consumption and coronary heart disease: Good habits may be more important than just good wine. Am J Epidemiol. 1996;143:1094-1098.
20. Criqui MH, Ringel BL. Does diet or alcohol explain the French paradox? Lancet. 1994;344(8939-8940):1719-1723.
21. Klatsky AL, Friedman GD, Armstrong MA, Kipp H. Wine, liquor, beer, and mortality. Am J Epidemiol. 2003;158(6):585-595.
22. Grønbaek M, Deis A, Sørensen TI, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits. BMJ. 1995;310(6988):1165-1169.
23. Truelsen T, Gronbaek M, Schnohr P, Boysen G. Intake of beer, wine, and spirits and risk of stroke: the Copenhagen city heart study. Stroke. 1998;29(12):2467-2472.
24. Renaud SC, Guéguen R, Siest G, Salamon R. Wine, beer, and mortality in middle-aged men from eastern France. Arch Intern Med. 1999;159(16):1865-1870.
25. Grønbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med. 2000;133(6):411-419.
26. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation. 2002;105(24):2836-2844.
27. Lamuela-Raventós RM, de la Torre-Boronat MC. Beneficial effects of white wines. Drugs Exp Clin Res. 1999;25(2-3):121-124.
28. Wallerath T, Poleo D, Li H, Förstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol. 2003;41(3):471-478.
29. Vogel RA. Vintners and vasodilators: are French red wines more cardioprotective? J Am Coll Cardiol. 2003;41(3):479-481.
30. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254:9355-9358.
31. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705-716.
32. Honda Z, Nakamura M, Miki I, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 1991;349:342-346.
33. Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med. 2001;11:139-142.
34. Androulakis N, Durand H, Ninio E, Tsoukatos DC. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J Lipid Res. 2005;46(9): 1923-1932.
35. Liapikos TA, Antonopoulou S, Karabina SP, et al. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. BBA-Lipid Lipid Metab. 1994;1212:353-360.
36. Braquet P, Hosford D, Koltz P, Guilbaud J, Paubert-Braquet M. Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids. 1991;26(12):1071-1075.
37. Bautista AP, Spitzer JJ. Platelet activating factor stimulates and primes the liver, Kupffer cells and neutrophils to release superoxide anion. Free Radic Res Commun. 1992;17(3):195-209.
38. Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation roducts in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11(3-4):103-112.
39. Heller R, Bussolino F, Ghigo D, et al. Human endothelial cells are target for platelet activating factor. Platelet activating factor induces platelet activating factor synthesis in human umbilical vein endothelial cells. J Immunol. 1992;149:3682-3688.
40. Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984;8(3-4): 137-142.
41. Jiang Y, Wen K, Zhou X, Schwegler-Berry D, Castranova V, He P. Three-dimensional localization and quantification of PAF-induced gap formation in intact venular microvessels. Am J Physiol Heart Circ Physiol. 2008;295(2):H898-H906.
42. Sánchez FA, Kim DD, Durán RG, Meininger CJ, Durán WN. Internalization of eNOS via caveolae regulates PAF-induced inflammatory hyperpermeability to macromolecules. Am J Physiol Heart Circ Physiol. 2008;295(4):H1642-H1648.
43. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
44. McMeekin SR, Dransfield I, Rossi AG, Haslett C, Walker TR. E-selectin permits communication between PAF receptors and TRPC channels in human neutrophils. Blood. 2006;107(12):4938-4945.
45. Kuijpers TW, Hakkert BC, Hart MH, Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. J Cell Biol. 1992;117(3): 565-572.
46. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The plateletactivating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30(5 Suppl):S294-301.
47. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 1995;95(5): 2297-2303.
48. McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981;67(3): 903-906.
49. Golino P, Ambrosio G, Ragni M, et al. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation. 1993;88(3):1205-1214.
50. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224): 1523-1528.
51. Waterhouse AL. Wine phenolics. Ann N Y Acad Sci. 2002;957: 21-36.
52. Dell'Agli M, Buscialà A, Bosisio E. Vascular effects of wine polyphenols. Cardiovasc Res. 2004;63(4):593-602.
53. Cordova AC, Jackson LS, Berke-Schlessel DW, Sumpio BE. The cardiovascular protective effect of red wine. J Am Coll Surg. 2005;200(3):428-439.
54. Howard A, Chopra M, Thurnham D, Strain J, Fuhrman B, Aviram M. Red wine consumption and inhibition of LDL oxidation: what are the important components? Med Hypotheses. 2002;59(1):101-104.
55. Cui J, Tosaki A, Cordis GA, et al. Cardioprotective abilities of white wine. Ann N Y Acad Sci. 2002;957:308-316.
56. Bertelli AAE, Migliori M, Panichi V, et al. Oxidative stress and inflammatory reaction modulation by white wine. Ann NY Acad Sci. 2002;957:295-301.
57. Vázquez-Agell M, Sacanella E, Tobias E, et al. Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr. 2007;137(10):2279-2284.
58. Li H, Förstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190:244-254.
59. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann N Y Acad Sci. 2008;1123: 134-145.
60. Mariano F, Bussolati B, Migliori M, Russo S, Triolo G, Camussi G. Platelet-activating factor synthesis by neutrophils, monocytes, and endothelial cells is modulated by nitric oxide production. Shock. 2003;19(4):339-344.
61. Kikuchi M, Shirasaki H, Himi T. Platelet-activating factor (PAF) increases NO production in human endothelial cells-real-time monitoring by DAR-4M AM. Prostaglandins Leukot Essent Fatty Acids. 2008;78(4-5):305-309.
62. Brkovic A, Sirois MG. Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J Cell Biochem. 2007;100(3):727-737.
63. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77(7):527-543.
64. Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-fed rabbits. Circulation. 1999;100:2254-2259.
65. Stoclet JC, Kleschyov A, Andriambeloson E, Diebolt M, Andriantsitohaina R. Endothelial no release caused by red wine polyphenols. J Physiol Pharmacol. 1999;50(4):535-540.
66. Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA, Das DK. Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem. 2008;56(20):9362-9373.
67. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106(13): 1652-1658.
68. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med. 2003;34(7):810-817.
69. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition Am J Physiol Heart Circ Physiol. 2006;291(4):H1694-1699.
70. Lee G, Na HJ, Namkoong S, et al. 4-O-methylgallic acid down-regulates endothelial adhesion molecule expression by inhibiting NF-kappaB-DNA-binding activity. Eur J Pharmacol. 2006;551(1-3):143-151.
71. Murase T, Kume N, Hase T, et al. Gallates inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of leukocyte adhesion molecules in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19(6):1412-1420.
72. Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, Wiedermann CJ. Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res. 2004;114(3): 185-194.
73. Sneddon AA, McLeod E, Wahle KW, Arthur JR. Cytokine-induced monocyte adhesion to endothelial cells involves platelet-activating factor: suppression by conjugated linoleic acid. Biochim Biophys Acta. 2006;1761(7):793-801.
74. Jeong YJ, Choi YJ, Choi JS, et al. Attenuation of monocyte adhesion and oxidised LDL uptake in luteolin-treated human endothelial cells exposed to oxidised LDL. Br J Nutr. 2007;97(3):447-457.
75. Araim O, Ballantyne J, Waterhouse A, Sumpio BE. Inhibition of vascular smooth muscle cell proliferation with red wine and red wine polyphenols. J Vasc Surg. 2002;35:1226-1232.
76. Imai Y, Clemmons DR. Roles of phosphatidylinositol-3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyribonucleic acid synthesis by insulin-like growth factor-I. Endocrinology. 1999;140(9):4228-4235.
77. Hedges JC, Dechert MA, Yamboliev IA, et al. A role for p38(MAPK)/ HSP27 pathway in smooth muscle cell migration. J Biol Chem. 1999;274:24211-24219.
78. Stoll LL, Spector AA. Interaction of platelet-activating factor with endothelial and vascular smooth muscle cells in coculture. J Cell Physiol. 1989;39:253-261.
79. Stengel D, O'Neil C, Brochériou I, et al. Receptor is preferentially expressed in a distinct synthetic phenotype of smooth muscle cells cloned from human internal thoracic artery: functional implications in cell migration. Biochem Biophys Res Commun. 2006;346(3): 693-699.
80. Wara AK, Mitsumata M, Yamane T, Kusumi Y, Yoshida Y. Gene expression in endothelial cells and intimal smooth muscle cells in atherosclerosis-prone or atherosclerosis-resistant regions of the human aorta. J Vasc Res. 2008;45(4):303-313.
81. Heery JM, Kozak M, Stafforini DM, et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96(5):2322-2330.
82. Akiba S, Yamaguchi H, Kumazawa S, Oka M, Sato T. Suppression of oxidized LDL-induced PDGF receptor beta activation by ginkgo biloba extract reduces MMP-1 production in coronary smooth muscle cells. J Atheroscler Thromb. 2007;14(5):219-225.
83. Stiko-Rahm A, Hultgårdh-Nilsson A, Regnström J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb. 1992;12(9): 1099-1109.
84. Iijima K, Yoshizumi M, Ouchi Y, et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. Circulation. 2000;101: 805-811.
85. Iijima K, Yoshizumi M, Hashimoto M, et al. Red wine polyphenols inhibit vascular smooth muscle migration through two distinct signaling pathways. Circulation. 2002;105:2404-2410.
86. Oak MH, Chataigneau M, Keravis T, et al. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol. 2003;23:1001-1007.
87. Ruf JC. Wine and polyphenols related to platelet aggregation and atherothrombosis. Drugs Exp Clin Res. 1999;25(2-3):125-131.
88. Pignatelli P, Pulcinelli FM, Celestini A, et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr. 2000;72(5):1150-1155.
89. Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol. 1987;36(3):317-322.
90. LandolfiR, Mower RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol. 1984;33(9):152515-152530.
91. Fragopoulou E, Nomikos T, Karantonis HC, et al. Biological activity of acetylated phenolic compounds. J Agric Food Chem. 2007;55(1): 80-89.
92. Fragopoulou E, Nomikos T, Antonopoulou S, Mitsopoulou CA, Demopoulos CA. Separation of biologically active lipids from red wine. J Agric Food Chem. 2000;48(4):1234-1238.
93. Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991;64(1):91-100.
94. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 1995;235(2): 207-219.
95. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta. 1996;246(1-2):163-182.
96. Rein D, Paglieroni TG, Pearson DA, et al. Cocoa and wine polyphenols modulate platelet activation and function. J Nutr. 2000;130 (8S Suppl):2120S-2126S.
97. Fragopoulou E, Nomikos T, Tsantila N, Mistopoulou A, Zabetakis I, Demopoulos CA. Biological activity of total lipids from red and white wine/must. J Agric Food Chem. 2001;49(11):5186-5193.
98. Fragopoulou E, Antonopoulou S, Nomikos T, Demopoulos CA. Structure elucidation of phenolic compounds from red/white wine with antiatherogenic properties. Biochim Biophys Acta. 2003;1632(1-3): 90-99.
99. Fragopoulou E, Antonopoulou S, Demopoulos CA. Biologically active lipids with antiatherogenic properties from white wine and must. J Agric Food Chem. 2002;50(9):2684-2694.
100. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395.
101. Maliba R, Lapointe S, Neagoe PE, Brkovic A, Sirois MG. Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways. Cell Signal. 2006;18(11): 1947-1957.
102. Barthomeuf C. Inhibition of S1P-induced angiogenesis, metastasis and inflammation by dietary polyphenols. Free Radic Biol Med. 2007;42(2):312-313.
103. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J. 1995;305(Pt 3):689-705.
104. Lindahl M, Tagesson C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation. 1993;17(5):573-582.
105. Gil B, Sanz MJ, Terencio MC, et al. Effects of flavonoids on Naja naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice. Life Sci. 1994;54(20):L333-L338.
106. Yanoshita R, Chang HW, Son KH, Kudo I, Samejima Y. Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996;45(11):546-549.
107. Balestrieri ML, Castaldo D, Balestrieri C, Quagliuolo L, Giovane A, Servillo L. Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003;44(2): 380-387.
108. Cao G, Prior A. Anthocyanins are detected in humanbplasma after oral administration of an elderberry extract. Clin Chem. 1999;45:574-576.
109. Manach C, Morand C, Crespy V, et al. Quercetin is recovered in human plasma as conjugated derivative which retain antioxidant properties. FEBS Lett. 1998;426:331-336.
110. Nigdikar S, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation. Am J Clin Nutr. 1998;68:258-265.
111. Leosdottir M, Nilsson PM, Nilsson JA, Berglund G. Cardiovascular event risk in relation to dietary fat intake in middle-aged individuals: data from The Malmö Diet and Cancer Study. Eur J Cardiovasc Prev Rehabil. 2007;14(5):701-706.
112. Karantonis HC, Antonopoulou S, Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis. 2006;16(3): 174-185.
113. Tsantila N, Karantonis HC, Perrea DN, et al. Antithrombotic and antiatherosclerotic properties of olive oil and olive pomace polar extracts in rabbits. Mediators Inflamm. 2007;2007:36204.
114. Antonopoulou S, Fragopoulou E, Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food. 2006;9(3):356-362.